Proactive Investors - Run By Investors For Investors

Hemogenyx Pharmaceuticals unveils new senior appointment

Andrew Wright, meanwhile, is coming in as financial controller and company secretary
Hemogenyx Pharmaceuticals unveils new senior appointment
Chief operating officer Lawrence Pemble is leaving

HemoGenyx Pharmaceuticals PLC (LONHEMO) said that its chief operating officer is leaving as it unveiled a new senior appointment.

Lawrence Pemble is exiting immediately. Andrew Wright, meanwhile, is coming in as financial controller and company secretary, a “non-board position”.

Wright is a trained accountant who is currently the director of corporate development for Thomas Murray, a post-trade capital markets data and advisory firm and is an executive director of Trayned Insight, a data science company serving the healthcare and pharmaceutical industries.

Hemogenyx chief executive, Dr Vladislav Sandler, said: "I am delighted to welcome Andrew to the team and look forward to his support as we continue to advance the development of our novel therapeutic products for patients with blood and severe autoimmune diseases.

“I would also like to extend my thanks to Lawrence for his contribution to the board and we wish him well in his next ventures."

The company is developing technology that could transform bone marrow transplantation and the treatment of blood diseases.

View full HEMO profile View Profile

HemoGenyx Pharmaceuticals Timeline

Related Articles

blood
January 29 2019
"With multiple collaboration agreements and investment from industry we view the company as undervalued," says Northland

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use